TippingPoint Biosciences

Active

First ever therapeutics for cancers driven by aberrant chromatin networks

What it does

Pioneering new therapies for diseases of chromatin dysfunction. There is a necessity for new types of treatments in diseases like Pediatric Diffuse Midlines Glioma (DMG). Cancer, Chromatin, Health, new solutions.

How it has moved

  • 2026-04-01 · seed · $4.5M

    TippingPoint Biosciences raised $4.5M in seed funding to advance its bioscience research and development. source

Next to it in Healthcare and bio · Cancer therapeutics via chromatin networks

  • Humane GenomicsY Combinator S21

    A platform to make artificial viruses as cancer therapeutics.

  • SFA TherapeuticsY Combinator S21

    Regulating the immune system to block cancer & autoimmune diseases

  • AOA DxY Combinator S21

    Blood Test for Early Detection of Ovarian Cancer

  • DigistainY Combinator S21

    Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow

  • MatrubialsY Combinator S21

    Developing milk-inspired therapeutics for infectious diseases

  • Promakhos TherapeuticsY Combinator S21

    A therapeutics platform for curing inflammatory disorders

  • ViAn TherapeuticsSOSV SOSV IndieBio SF 14

    Topical antiangiogenic peptide for retinal vascular diseases

  • FREZENT Biological SolutionsSOSV SOSV IndieBio NY 07

    Changing the prognosis for patients with advanced stage cancer